Fabien B Vincent¹, Eric F Morand² and Fabienne Mackay¹

Recently, the B cell has emerged as a cornerstone of systemic lupus erythematosus (SLE) pathogenesis. This has been highlighted by studies of the cytokine B-cell-activating factor of the tumour necrosis factor (TNF) family (BAFF), a crucial factor regulating B-cell maturation, survival and function. Overexpression of BAFF in mice leads to the development of an SLE-like disease, independent of T cells but instead relying on innate immunity mechanisms. Moreover, BAFF has been shown to be elevated in the serum of patients suffering from autoimmune conditions, especially SLE, and may correlate with disease activity. These findings challenge the previous notion that T:B-cell collaboration is the sole driver of SLE. In recent years, controlled trials have for the first time tested targeted therapeutics for SLE. However, agents designed to target B cells failed to meet primary endpoints in clinical trials in SLE, suggesting that a more complex role for B cells in SLE awaited elucidation. By contrast, on 9 March 2011, the US Food and Drug Administration approved belimumab, a fully human anti-BAFF monoclonal antibody, as a new B-cell-specific treatment for SLE. This article will review over 10 years of research on the BAFF system, key findings that led to this recent positive clinical outcome and propose a model potentially explaining why this B-cell-specific therapy has yielded positive results in clinical trials. We will also review promising therapies presently in clinical trials targeting innate immunity, which are likely to revolutionize SLE management towards a personalized and targeted therapy approach.

 

 

1. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–2228. | Article | PubMed | ISI | ChemPort |
2. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–980. | Article | PubMed | ISI | ChemPort |
3. Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 3623–3632. | Article | PubMed | ChemPort |
4. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955–1959. | PubMed |
5. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 853–865. | Article | PubMed | ISI | ChemPort |
6. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435: 452–458. | Article | PubMed | ISI | ChemPort |
7. Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004; 113: 4–13. | Article | PubMed | ChemPort |
8. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ et al. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J Exp Med 2007; 204: 1959–1971. | Article | PubMed | ISI | ChemPort |
9. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14: 573–582. | Article | PubMed | ISI | ChemPort |
10. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065–1067. | Article | PubMed | ISI | ChemPort |
11. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6–10. | PubMed | ISI | ChemPort |
12. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12: R48. | Article | PubMed |
13. Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 997–1002. | Article | PubMed |
14. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 2010; 135: 118–124. | Article | PubMed |
15. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453–2459. | Article | PubMed | ISI | ChemPort |
16. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Shen Y-L et al. Association of BLyS™ with measures of disease activity in a prospective SLE observational study. Arthritis Rheum 2004; 50: S603. | Article |
17. Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 2004; 3: 516–523. | Article | PubMed |
18. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303–306. | Article | PubMed | ISI | ChemPort |
19. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254. | Article | PubMed |
20. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188–1195. | Article | PubMed | ISI | ChemPort |
21. Bossingham D. Systemic lupus erythematosus in the far north of Queensland. Lupus 2003; 12: 327–331. | Article | PubMed |
22. Ong C, Nicholls K, Becker G. Ethnicity and lupus nephritis: an Australian single centre study. Intern Med J 2011; 41: 270–278. | Article | PubMed |
23. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–1533. | Article | PubMed | ISI | ChemPort |
24. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697–1710. | Article | PubMed | ISI | ChemPort |
25. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747–1756. | Article | PubMed | ISI | ChemPort |
26. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453–1466. | Article | PubMed | ISI | ChemPort |
27. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231–264. | Article | PubMed | ISI | ChemPort |
28. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9: 491–502. | Article | PubMed | ISI | ChemPort |
29. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235–246. | Article | PubMed | ISI | ChemPort |
30. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108: 383–394. | Article | PubMed | ISI | ChemPort |
31. Cachero TG, Schwartz IM, Qian F, Day ES, Bossen C, Ingold K et al. Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry 2006; 45: 2006–2013. | Article | PubMed |
32. Gavin AL, Ait-Azzouzene D, Ware CF, Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003; 278: 38220–38228. | Article | PubMed |
33. Gavin AL, Duong B, Skog P, Ait-Azzouzene D, Greaves DR, Scott ML et al. deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005; 175: 319–328. | PubMed |
34. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314–4321. | PubMed | ISI | ChemPort |
35. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198–204. | Article | PubMed | ISI | ChemPort |
36. Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001; 194: 1691–1697. | Article | PubMed | ISI | ChemPort |
37. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168: 5993–5996. | PubMed | ISI | ChemPort |
38. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822–829. | Article | PubMed | ISI | ChemPort |
39. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119: 1066–1073. | Article | PubMed | ISI | ChemPort |
40. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995–999. | Article | PubMed | ISI | ChemPort |
41. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; 17: 515–524. | Article | PubMed | ISI | ChemPort |
42. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632–637. | Article | PubMed | ISI | ChemPort |
43. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785–798. | Article | PubMed | ISI | ChemPort |
44. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005; 174: 5537–5544. | PubMed | ChemPort |
45. Ozcan E, Garibyan L, Lee JJ, Bram RJ, Lam KP, Geha RS. Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J Allergy Clin Immunol 2009; 123: 1277–1286 e1275. | Article | PubMed |
46. Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R167. | Article | PubMed | ChemPort |
47. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313–1319. | Article | PubMed | ISI | ChemPort |
48. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 2005; 25: 189–201. | Article | PubMed | ISI | ChemPort |
49. Gu D, Ge J, Du W, Xue F, Chen Z, Zhao H et al. Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications. Autoimmunity 2009; 42: 692–698. | Article | PubMed | ISI |
50. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM et al. BAFF is produced by astrocytes and upregulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195–200. | Article | PubMed | ISI | ChemPort |
51. Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 2007; 65: 92–98. | Article | PubMed | ChemPort |
52. Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y et al. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007; 46: 53–60. | Article | PubMed | ChemPort |
53. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007; 34: 2056–2062. | PubMed | ChemPort |
54. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096–1103. | Article | PubMed | ISI | ChemPort |
55. George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10: R97. | Article | PubMed |
56. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475–3486. | Article | PubMed | ISI |
57. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6. | Article | PubMed |
58. Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum 2009; 60: 3400–3409. | Article | PubMed |
59. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115: 196–202. | Article | PubMed | ISI | ChemPort |
60. Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394–399. | Article | PubMed | ISI | ChemPort |
61. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–723. | Article | PubMed | ISI | ChemPort |
62. Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006; 8: R51. | Article | PubMed |
63. Giordani L, Sanchez M, Libri I, Quaranta MG, Mattioli B, Viora M. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production. J Leukoc Biol 2009; 86: 261–271. | Article | PubMed | ChemPort |
64. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005; 174: 4043–4050. | PubMed |
65. Ittah M, Miceli-Richard C, Gottenberg JE, Sellam J, Eid P, Lebon P et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008; 38: 1058–1064. | Article | PubMed | ChemPort |
66. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417–428. | Article | PubMed | ISI | ChemPort |
67. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R et al. Upregulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008; 152: 482–487. | Article | PubMed |
68. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54: 3601–3611. | Article | PubMed | ISI | ChemPort |
69. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513–520. | Article | PubMed | ISI | ChemPort |
70. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253–3265. | Article | PubMed | ISI | ChemPort |
71. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721–731. | Article | PubMed | ISI | ChemPort |
72. Van Vollenhoven R, Zamani O, Wallace D et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE:BLySS-76 study. Ann Rheum Dis 2010; 69: 74.
73. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 361–371. | PubMed | ISI | ChemPort |
74. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007; 179: 3351–3361. | PubMed | ChemPort |
75. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222–233. | Article | PubMed | ISI | ChemPort |
76. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458. | PubMed | ISI | ChemPort |
77. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129–140. | Article | PubMed | ISI | ChemPort |
78. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044–3056. | Article | PubMed | ISI | ChemPort |
79. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092–6099. | PubMed | ISI | ChemPort |
80. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172: 3422–3427. | PubMed | ISI | ChemPort |
81. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; 45: 144–158. | Article |
82. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566–1575. | Article | PubMed | ChemPort |
83. Furie R, Petri M, Zamani O, Cervera R, Wallace JD, Tegzova D et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918–3930. | Article | PubMed |
84. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62: 201–210. | Article | PubMed | ISI | ChemPort |
85. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168–1178. | Article | PubMed | ISI | ChemPort |
86. Zhu F-G, Yu D, Kandimalla ER, La Monica N, Agrawal S. Treatment with IMO-3100, a novel TLR7 and TLR9 dual antagonist, inhibits disease development in lupus prone NZBW/F1 mice. Keystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity 2011.
87. Sullivan T, Atiee G, Bhagat L, Jiang W, Murphy J, Ostavnenko N et al. A novel Toll-like receptor antagonist for autoimmune and inflammatory diseases: safety and pharmacodynamics in a multiple-dose phase 1 clinical trial. Keystone Symposia Meeting: Immunoregulatory Networks, April 2011.
88. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon {alpha} monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011; 70: 1905–1913. | Article | PubMed |
89. Hofer T, Muehlinghaus G, Moser K, Yoshida T, H EM, Hebel K et al. Adaptation of humoral memory. Immunol Rev 2006; 211: 295–302. | Article | PubMed |
90. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723–732. | Article | PubMed | ISI | ChemPort |
91. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011–1016. | Article | PubMed | ISI | ChemPort |
92. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817–826. | PubMed | ISI | ChemPort |
93. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524–3534. | PubMed | ISI | ChemPort |
94. Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000; 165: 2987–2996. | PubMed | ISI | ChemPort |
95. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 15178–15183. | Article | PubMed | ChemPort |
96. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 2913–2916. | PubMed | ISI | ChemPort |
97. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470–1480. | PubMed | ISI | ChemPort |
98. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995; 47: 122–130. | Article | PubMed | ISI | ChemPort |
99. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119: 296–305. | Article | PubMed |
100. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24: 579–590. | Article | PubMed |
101. Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM. Pharmacological intervention in antibody mediated disease. Lupus 1996; 5: 158–159. | Article | PubMed | ISI | ChemPort |
102. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499–2506. | PubMed | ISI | ChemPort |
103. Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T et al. Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum 2011 (e-pub ahead of print).
104. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008; 58: 1433–1444. | Article | PubMed | ISI | ChemPort |
105. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37: 289–297. | Article | PubMed | ChemPort |
106. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70 K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003; 33: 287–296. | Article | PubMed | ChemPort |
107. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74. | Article | PubMed | ChemPort |
108. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009; 18: 547–555. | Article | PubMed | ChemPort |
109. Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56: 4142–4150. | Article | PubMed | ISI | ChemPort |
110. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451–1454. | Article | PubMed | ChemPort |
111. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008; 58: 2470–2480. | Article | PubMed | ChemPort |
112. Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun 2009; 33: 77–82. | Article | PubMed | ChemPort |
113. Muller S, Monneaux F, Schall N, Rashkov RK, Oparanov BA, Wiesel P et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum 2008; 58: 3873–3883. | Article | PubMed | ChemPort |
114. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2983–2988. | Article | PubMed | ISI | ChemPort |
115. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161–3169. | Article | PubMed | ISI | ChemPort |
116. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542–552. | Article | PubMed |
117. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 3077–3087. | Article | PubMed |
118. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719–727. | Article | PubMed | ISI | ChemPort |
119. Kalunian KC, Davis Jr JC, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 3251–3258. | Article | PubMed | ISI | ChemPort |

转载本文请联系原作者获取授权，同时请注明本文来自吴恬伏科学网博客。
链接地址：https://blog.sciencenet.cn/blog-608831-529542.html

上一篇：文化大革命留给中国史学家的研究命题
下一篇：网友和朋友